Brief: Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients
20/05/2020 12:46
May 20 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY AND MERCK TO COLLABORATE ON
IMMUNO-ONCOLOGY
STUDY EVALUATING SRF617, TARGETING CD39 IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMOR PATIENTS
* SURFACE ONCOLOGY INC - COMBINATION WILL BE STUDIED AS A
COMPONENT OF FIRST-IN-HUMAN PHASE 1/1B STUDY OF SRF617
Source text for Eikon: ID:nGNX9h9ZM7
Further company coverage: SURF.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing